Yesterday, Novartis released new data from its head-to-head CLARITY study that shows that its secukinumab (Cosentyx) was significantly more effective than ustekinumab (Stelara) in the treatment of psoriasis in delivering clear or almost clear skin at 12 and 16 weeks.
Yesterday, Novartis released new data from its head-to-head CLARITY study that shows that its secukinumab (Cosentyx) was significantly more effective than ustekinumab (Stelara) in the treatment of psoriasis in delivering clear or almost clear skin at 12 and 16 weeks.
Secukinumab is a targeted biologic therapy that inhibits IL-17A, a cytokine involved in inflammation of entheses.
The results of the CLARITY study show that 66.5% and 72.3% of patients treated with secukinumab (P <.0001) achieved both co-primary endpoints of a response of 90 on the Psoriasis Area and Severity Index (PASI90) and a score of score of 0/1 on the Investigator’s Global Assessment (IGA) (modified 2011), a 5-point tool used to evaluate plaque psoriasis severity, respectively. These results are compared with 47.9% and 55.4%, respectively, of patients treated with ustekinumab achieving PASI90 and IGA 0/1 (P <.0001).
In addition, all key secondary endpoints in the CLARITY study were met, and the safety profile of secukinumab was in line with its known safety profile. The newly released data support findings from the CLEAR study, which found secukinumab to be superior to ustekinumab in achieving sustained skin clearance at 52 weeks.
“These data add to the robust body of evidence supporting the use of Cosentyx to treat moderate to severe plaque psoriasis,” said Mark Lebwohl, MD, chairman of the Waldman department of dermatology at the Icahn School of Medicine at Mount Sinai Hospital in New York. “With these findings clinicians can have even greater confidence including Cosentyx in their treatment plans.”
To date, more than 125,000 patients worldwide have been prescribed secukinumab in the post-marketing setting across all indications. According to Novartis’ third quarter results in 2017, Cosentyx reached $556 million in net sales. Its fourth quarter 2017 results will be announced shortly.
Novartis also recently announced that it is initiating the SURPASS trial; SUPRASS is set to be a head-to-head clinical trial of secukinumab versus a proposed biosimilar adalimumab (referencing Humira and being developed by Sandoz, a Novartis division) in patients with ankylosing spondylitis. Positive results in this trial could potentially make secukinumab a top competitor for an increased share of the market for inflammatory disease treatment.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Sintilimab, Bevacizumab Biosimilar, HAIC Improves Survival in Patients With Unresectable HCC
April 14th 2024Positive results of sintilimab, IBI305, and hepatic arterial infusion chemotherapy (HAIC) treatment showed shrinking tumors and previously converting inoperable hepatocellular carcinoma (HCC) to resectable HCC with manageable adverse effects.